Specific acute migraine treatment: Ergotamine and triptans

Migraine and Other Headache Disorders

Volumn , Issue , 2016, Pages 289-310

  Diener, Hans Christoph ^a   Limmroth, Volker ^b  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 46249086470     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (124)

1. Tfelt-Hansen P. Preliminary analysis of randomized placebo-controlled clinical trials with newer 5-HT1D receptor agonists for the treatment of migraine attacks. In: Olesen J, Tfelt-Hansen P, eds. Headache Treatment: Trial Methodology and New Drugs. New York: Lippincott-Raven 1997:6:253-256.
2. Ferrari MD, Roon KI, Lipton RB, Goadsby P. Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 2001; 358:1668-1675.
3. Belsey JB. Reconciling effectiveness and tolerability in oral triptan therapy: a qualitative approach to decision making in migraine management. J Clin Res 2001; 4:105-125.
4. Tfelt-Hansen P, Block G, Dahlof C, et al. for the International Headache Society Clinical Trials Subcommittee. Guidelines for controlled trials of drugs in migraine: second edition. Cephalalgia 2000; 20:765-786.
5. Tfelt-Hansen P, Saxena PR, Dahlof C, et al. Ergotamine in the acute treatment of migraine. A review and European consensus. Brain 2000; 123:9-18.
6. Dahlof C. Placebo-controlled clinical trials with ergotamine in the acute treatment of migraine. Cephalalgia 1993; 13:166-171.
7. McNeely W, Goa KL. Diclofenac-potassium in migraine. Drugs 1999; 57:991-1003.
8. Titus F, Lainez J, Leira R, Diez E, Monteiro P, Dexeus I. Double-blind, multicentric, comparative study of lysin acetylsalicylate (1620 mg equivalent to 900 mg aspirin) | metoclopramide (10 mg) versus ergotamine (2 mg) + caffeine (200 mg) in the treatment of migraine. Cephalalgia 1999; 19:371.
9. The Multinational Oral Sumatriptan Cafergot Comparative Study Group. A randomized, double-blind comparison of sumatriptan and Cafergot in the acute treatment of migraine. Eur Neurol 1991; 31:314-322.
10. Diener HC, Reches A, Pascual J, Jansen J-P, Pitei D, Steiner T. on behalf of the Eletriptan Cafergot Comparative Study Group. Efficacy, tolerability and safety of oral eletriptan and ergotamine plus caffeine (Cafergot) in the acute treatment of migraine: a multicenter, randomized, double-blind, placebo-controlled comparison. Eur Neurol 2002; 47:99-107.
11. Christie S, Gobel H, Mateos V, Allen C, Vrijens F, Shivaprakash M. Rizatriptan-Ergotamine/Caffeine Preference Study Group. Crossover comparison of efficacy and preference for rizatriptan 10 mg versus ergotamine/caffeine in migraine. Eur Neurol 2002; 49:20-29.
12. Horton BT, Peters GA. Clinical manifestations of excessive use of ergotamine preparations and management of withdrawal effect: report of 52 cases. Headache 1963; 3:214-226.
13. Diener HC, Limmroth V. Medication-overuse headache: a worldwide problem. Lancet Neurol 2004; 3:475-483.
14. Olesen J, Bousser M-G, Diener H, et al. for the International Headache Society. The International Classification of Headache Disorders. 2nd ed. Cephalalgia 2004; 24(suppl 1):1-160.
15. Diener HC, Katsarava Z. Medication overuse headache. Curr Med Res Opin 2002; 17:17-21.
16. Tfelt-Hansen P. Efficacy and adverse events of subcutaneous, oral, and intranasal sumatriptan used for migraine treatment: a systematic review based on number needed to treat. Cephalalgia 1998; 18:532-538.
17. Pfaffenrath V, Cunin G, Sjonell G, Prendergast S. Efficacy and safety of sumatriptan tablets (25 mg, 50 mg, and 100 mg) in the acute treatment of migraine: defining the optimum doses of oral sumatriptan. Headache 1998; 38:184-190.
18. Moore KHP, Hussey EK, Shaw S, Fuseau E, Duquesnoy C, Pakes GE. Safety, toler-ability, and pharmacokinetics of sumatriptan in healthy subjects following ascending single intranasal doses and multiple intranasal doses. Cephalalgia 1997; 17:541-550.
19. Becker WJ. on behalf of the Study Group. A placebo-controlled, dose-defining study of sumatriptan nasal spray in the acute treatment of migraine. Cephalalgia 1995; 15(suppl 14):271-276.
20. Ryan R, Elkind A, Baker CC, Mullican W, DeBussy S, Asgharnejad M. Sumatriptan nasal spray for the acute treatment of migraine. Neurology 1997; 49:1225-1230.
21. Ashford E, Salonen R, Saiers J, Woessner M. Consistency of response to sumatriptan nasal spray across patient subgroups and migraine types. Cephalalgia 1998; 18:273-277.
22. Gobel H. on behalf of the Study Group. A placebo-controlled, dose defining study of sumatriptan suppositories in the acute treatment of migraine. Cephalalgia 1995; 15(suppl 14):232.
23. Tepper SJ, Cochran A, Hobbs S, Woessner M. on the behalf of the S2B351 Study Group. Sumatriptan suppositories for the acute treatment of migraine. Int J Clin Pract 1998; 52:31-35.
24. Barrows C, Saunders W, Austin R, Putnam G, Mansbach H, for the SNAP Study Group. The sumatriptan/naratriptan aggregated patient (SNAP) database: aggregation, validation and application. Cephalalgia 2004; 24:586-595.
25. Diener HC, Ferrari M, Mansbach H. for the SNAP Database Study Group. Predicting the response to sumatriptan: the Sumatriptan Naratriptan Aggregate Patient Database. Neurology 2004; 63:520-524.
26. Walls C, Lewis A, Bullman J, et al. Pharmokinetic profile of a new form of sumatriptan tablets in healthy volunteers. Curr Med Res Opin 2004; 20:803-809.
27. Schulman E, Dermott K. Sumatriptan plus metoclopramide in triptan-nonresponsive migraineurs. Headache 2003; 43:729-733.
28. Perry CM, Markham A. Sumatriptan. An updated review of its use in migraine. Drugs 1998; 55:889-922.
29. Joffe RT, Sokolov ST. Co-administration of fluoxetine and sumatriptan: the Canadian experience. Acta Psychiatr Scand 1997; 95:551-552.
30. Freitag FG, Diamond S, Diamond M, Urban G, Pepper B. Subcutaneous sumatriptan in patients treated with monoamine oxidase inhibitors and other prophylactic agents. Headache Q 1998; 9:165-171.
31. Klassen A, Elkind A, Asharnejad M, Webster C, Laurenza A. on behalf of the Naratriptan S2WA3001 Study Group. Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, parallel-group study. Headache 1997; 37:630-645.
32. Mathew NT, Asgharnejad M, Peykamian M, Laurenza A. on behalf of the Naratriptan S2WA3001 Study Group. Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, crossover study. Neurology 1997; 49:1485-1490.
33. Gunasekara NS, Wiseman LR. Naratriptan. CNS Drugs 1997; 8:402-408.
34. Goadsby PJ. Treatment of acute migraine attacks with naratriptan. In: Diener H-C, ed. Drug Treatment of Migraine and other Frequent Headaches. Basel: Karger AG, 2000:134-140.
35. Heywood J, Bomhof MAM, Pradalier A, Thaventhiran L, Winter P, Hassani H. Tolerability and efficacy of naratriptan tablets in the acute treatment of migraine attacks for 1 year. Cephalalgia 2000; 20:470-474.
36. Sheftell F, O'Quinn S, Watson C, Pait D, Winter P. Low migraine headache recurrence with naratriptan: clinical parameters related to recurrence. Headache 2000; 40:103-110.
37. Goadsby PJ, Knight YE. Direct evidence for central sites of action of zolmitriptan (311C90): an autoradiographic study in cat. Cephalalgia 1997; 17:153-158.
38. Ellrich J, Messlinger K, Chiang CY, Hu JW. Modulation of neuronal activity in the nucleus raphe magnus by the 5-HT1-receptor agonist naratriptan in rat. Pain 2001; 90:227-231.
39. Ferrari MD. 311C90: increasing the options for the therapy with effective acute antimigraine 5HT1B/D receptor agonists. Neurology 1997; 48(suppl 3):21-24.
40. Rapoport AM, Ramadan NM, Adelmann JU, et al. on behalf of The 017 Clinical Trial Study Group. Optimizing the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine. A multicenter, double-blind, placebo-controlled, dose-finding study. Neurology 1997; 49:1210-1218.
41. Dahlof C, Diener HC, Goadsby PJ, et al. Zolmitriptan, a 5-HT1B/D receptor agonist for the acute oral treatment of migraine: a multicenter, dose-range finding study. Eur J Neurol 1998; 5:535-543.
42. Geraud G, Olesen J, Pfaffenrath V, et al. on behalf of the Study Group. Comparison of the efficacy of zolmitriptan and sumatriptan: issues in migraine trial design. Cephalalgia 2000; 20:30-38.
43. Solomon GD, Cade RK, Klapper JA, Earl NL, Saper JR, Ramadan NM. on behalf of The 042 Clinical Trial Study Group. Clinical efficacy and tolerability of 2.5 mg zolmitriptan for the acute treatment of migraine. Neurology 1997; 49:1219-1225.
44. Schoenen J, Sawyer J. Zolmitriptan (Zomig, 311C90), a novel dual central and peripheral 5HT1B/1D agonist: an overview of efficacy. Cephalalgia 1997; 17(suppl 18):28-40.
45. The International 311C90 Long-Term Study Group. The long-term tolerability and efficacy of oral zolmitriptan (Zomig, 311C90) in the acute treatment of migraine. An international study. Headache 1998; 38:173-183.
46. Becker WJ, Lee D. Zolmitriptan nasal spray is effective, fast-acting and well tolerated during both, short- and long-term treatment. Cephalalgia 2001; 21:271.
47. Dowson AJ, Boes-Hansen S, Farkkila AM. Zolmitriptan nasal spray is fast-acting and highly effective in the acute treatment of migraine. Eur J Neurol 2000; 7(suppl 3):82.
48. Sorensen J, Bergstrom M, Antoni A, et al. Distribution of 11C-zolmitriptan nasal spray assessed by positron emission tomography (PET). Eur J Neurol 2000; 7(suppl 3):82.
49. Edmeads JG, Millson DS. Tolerability profile of zolmitriptan (Zomig; 311C90), a novel dual central and peripherally acting 5HT1B/1D agonist. Cephalalgia 1997; 17:41-52.
50. Rolan P. Potential drug interactions with the novel antimigraine compound zolmitriptan (Zomig (R), 311C90). Cephalalgia 1997; 17(suppl 18):21-27.
51. 1B/1D-agonist zolmitriptan in healthy young and elderly men and women. Clin Pharmacol Ther 1998; 63(3):342-353.
52. Stark S, Spierings ELH, McNeal S, Putnam GP, Bolden-Watson CP, O'Quinn S. Naratriptan efficacy in migraineurs who respond poorly to oral sumatriptan. Headache 2000; 40:513-520.
53. Pascual J, Munoz R, Leira R. An open preference study with sumatriptan 50 mg and zolmitriptan 2.5mg in 100 migraine patients. Cephalalgia 2001; 21:680-684.
54. Visser WH, Terwindt GM, Reines SA, Jiang K, Lines CR, Ferrari MD. for the Dutch/U.S. Rizatriptan Study Group. Rizatriptan vs sumatriptan in the acute treatment of migraine. A placebo-controlled, dose-ranging study. Arch Neurol 1997; 53: 1132-1137.
55. Teall J, Tuchmann M, Cutler N, et al. on behalf of the Rizatriptan 022 Study Group. Rizatriptan (MAXALT) for the acute treatment of migraine and migraine recurrence. A placebo-controlled, outpatient study. Headache 1998; 38:281-287.
56. Tfelt-Hansen P, Teall J, Rodriguez F, et al. on behalf of the Rizatriptan 030 Study Group. Oral rizatriptan versus oral sumatriptan: a direct comparative study in the acute treatment of migraine. Headache 1998; 38:748-755.
57. Goldstein J, Ryan R, Jiang K, et al. and the Rizatriptan Protocol 046 Study Group. Crossover comparison of rizatriptan 5 mg and 10 mg versus sumatriptan 25 and 50 mg in migraine. Headache 1998; 38:737-747.
58. Kramer MS, Matzura-Wolfe D, Polis A, et al. Rizatriptan Multiple Attack Study Group. A placebo-controlled crossover study of rizatriptan in the treatment of multiple migraine attacks. Neurology 1998; 51:773-781.
59. Pascual J, Vega P, Diener HC, Allen C, Vrijens F, Patel K. and the Rizatriptan-Zolmitriptan Study Group. Comparison of rizatriptan 10 mg vs. zolmitriptan 2.5 mg in the acute treatment of migraine. Cephalalgia 2000; 20:455-461.
60. Bomhof M, Paz J, Legg N, Allen C, Vandormael K, Patel K. Comparison of rizatriptan 10mg vs. naratriptan 2.5mg in migraine. Eur Neurol 1999; 42:173-179.
61. Goadsby PJ. Rizatriptan in acute treatment of migraine: update on new comparative data. Cephalalgia 2000; 20(suppl 1):10-15.
62. Ahrens SP, Farmer MV, Williams D, et al. Rizatriptan Wafer Protocol 049 Study Group. Efficacy and safety of rizatriptan wafer for the acute treatment of migraine. Cephalalgia 1999; 19:525-530.
63. Adelman JU, Mannix LK, Seggern von RL. Rizatriptan tablet versus wafer: patient preference. Headache 2000; 40:371-372.
64. Klapper JA, O'Connor S. Rizatriptan wafer-sublingual vs. placebo at the onset of acute migraine. Cephalalgia 2000; 20:585-587.
65. Diener HC, McHarg A. Pharmacology and efficacy of eletriptan for the treatment of migraine attacks. Int J Clin Pract 2000; 54:670-674.
66. Goadsby PJ, Ferrari MD, Olesen J, et al. for the Eletriptan Steering Committee. Eletriptan in acute migraine: a double-blind, placebo-controlled comparison to sumatriptan. Neurology 2000; 54:156-163.
67. Milton KA, Kleinermans D, Scott N, Cooper JDH. The bioequivalence of standard sumatriptan tablets and two encapsulated forms of sumatriptan. Int J Pharm Med 2001; 15:21-26.
68. Salonen R, Kori S, Scott A, Richardson MS. Encapsulated sumatriptan is not bioequivalent to commercial sumatriptan. Headache 2003; 43:923-924 [comment]; 924-928 [author reply].
69. Diener HC. Eletriptan therapy. In: Diener HC, ed. Drug Treatment of Migraine and Other Headaches. Basel: Karger, 2000:184-189.
70. Garcia-Ramos GME, Hilliard B, Bordini CA, Leston J, Hettiarachchi J. Comparative efficacy of eletriptan vs. naratriptan in the acute treatment of migraine. Cephalalgia 2003; 23:869-876.
71. Steiner T, Diener H, MacGregor E, Schoenen J, Muirhead N, Sikes C. Comparative efficacy of eletriptan and zolmitriptan in the acute treatment of migraine. Cephalalgia 2003; 23:942-952.
72. Goldstein J, Tiseo P, Denaro J, Sikes C. Efficacy of eletriptan in migraine patients reporting unsatisfactory response to rizatriptan. Poster presentation at the 7th Biennial European Headache Federation Congress, 2004.
73. Diamond M, Hettiarachchi J, Hilliard B, Sands G, Nett R. Effectiveness of eletriptan in acute migraine: primary care for Excedrin nonresponders. Headache 2004; 44:209-216.
74. Cabarrocas X, Zayas JM. on behalf of the Almotriptan Oral Study Group. Efficacy data on oral almotriptan, a novel 5-HT1B/D agonist. Headache 1998; 38:377.
75. Pascual J. Therapy with other triptans: almotriptan. In: Diener HC, ed. Drug Treatment of Migraine and Other Headaches. Basel: Karger, 2000:197-205.
76. Pascual J, Falk RM, Piessens F, et al. Consistent efficacy and tolerability of almotriptan in the acute treatment of multiple migraine attacks: results of a large, randomized, double-blind, placebo-controlled study. Cephalalgia 2000; 20:588-596.
77. Cabarrocas X, Zayas JM, Suris M. on behalf of the Almotriptan Oral Study Group. Equivalent efficacy of oral almotriptan, a new 5-HT1B/D agonist, compared with sumatriptan 100 mg. Headache 1998; 38:377-378.
78. Spierings E, Gomez-Mancilla B, Grosz D, Rowland C, Whaley F, Jirgens K. Oral almotriptan vs. oral sumatriptan in the abortive treatment of migraine: a double-blind, randomized, parallel-group, optimum-dose comparison. Arch Neurol 2001; 58:944-950.
79. Mathew NT. for the Oral Almotriptan Study Group. A long-term open-label study of oral almotriptan 12.5 mg for the treatment ofacute migraine. Headache 2002; 42:32-40.
80. Cabarrocas X, Esbri R, Peris F, Ferrer P. Long-term efficacy and safety of oral almotriptan: interim analysis of a 1-year open study. Headache 2001; 41:57-62.
81. Brown AM, Ho M, Thomas DR, Parson AA. Comparison of functional effects of frovatriptan, sumatriptan and naratriptan on human recombinant 5-HT1 and 5-HT7 receptors. Headache 1998; 38:376.
82. Goldstein J, Elkind A, Keywood C, Klapper J, Ryan R. A low dose range-finding study of frovatriptan: a potent selective 5-HT1B/D agonist for the acute treatment of migraine. Headache 1998; 38:382-383.
83. Goldstein J, Keywood C. and the 251/96/14 Study Group. Frovatriptan for the acute treatment of migraine: a dose-finding study. Headache 2002; 42:41-48.
84. Ferrari MD. How to assess and compare drugs in the management of migraine: success rates in terms of response and recurrence. Cephalalgia 1999; 19(suppl 23):2-8.
85. Visser WH, Jaspers N, de Vriend RHM, Ferrari MD. Risk factors for headache recurrence after sumatriptan: a study in 366 migraine patients. Cephalalgia 1996; 16:264-269.
86. McDavis HL, Hutchison J. Frovatriptan Phase III Investigators. Frovatriptan- a review of overall clinical efficacy. Cephalalgia 1999; 19:363-364.
87. The Oral Sumatriptan and Aspirin plus Metoclopramide Comparative Study Group. A study to compare oral sumatriptan with oral aspirin plus oral metoclopramide in the acute treatment of migraine. Eur Neurol 1992; 32:177-184.
88. Tfelt-Hansen P, Henry P, Mulder LJ, Schaeldewaert RG, Schoenen J, Chazot G. The effectiveness of combined oral lysine acetylsalicylate and metoclopramide compared with oral sumatriptan for migraine. Lancet 1995; 346:923-926.
89. Geraud G, Compagnon A, Rossi A. The COZAM Study Group. Zolmitriptan versus a combination of acetylsalicylic acid and metoclopramide in the acute oral treatment of migraine: a double-blind, randomized, three-attack study. Eur Neurol 2002; 47:88-98.
90. Dib M, Massiou H, Weber M, Henry P, Garcia-Acosta S, Bousser M. Bi-Profenid Migraine Study Group. Efficacy of oral ketoprofen in acute migraine: a double-blind randomized clinical trial. Neurology 2002; 58:1660-1665.
91. Diener HC, Eikermann A, Gessner U, et al. Efficacy of 1,000mg effervescent acetylsalicylic acid and sumatriptan in treating associated migraine symptoms. Eur Neurol 2004; 52:50-56.
92. Diener HC, Bussone G, de Liano H, et al. The EMSASI Study Group. Placebo-controlled comparison of effervescent acetylsalicylic acid, sumatriptan and ibuprofen in the treatment of migraine attacks. Cephalalgia 2004; 24:947-954.
93. Ryan RE, Diamond S, Giammarco RAM, Aurora SK, Reed RC, Fletcher PE. Efficacy of zolmitriptan at early time points for acute treatment of migraine and treatment of recurrence. CNS Drugs 2000; 13:215-226.
94. Pascual J, Cabarrocas X. Within-patient early versus delayed treatment of migraine attacks with almotriptan: the sooner the better. Headache 2002; 42:28-31.
95. Cady RK, Sheftell F, Lipton RB, et al. Effect of early intervention with sumatriptan on migraine pain: retrospective analyses of data from three clinical trials. Clin Ther 2000; 22:1035-1048.
96. Mathew N. Early intervention with almotriptan improves sustained pain-free response in acute migraine. Headache 2003; 43:1075-1079.
97. Burstein R, Yarnitsky D, Goor-Aryeh I, Ransil BJ, Bajwa ZH. An association between migraine and cutaneous allodynia. Ann Neurol 2000; 47:614-624.
98. Burstein R, Collins B, Jakubowski M. Defeating migraine pain with triptans: a race against development of cutaneous allodynia. Ann Neurol 2004; 55:19-26.
99. Krymchantowski AV, Adriano M, Fernandes D. Tolfenamic acid decreases migraine recurrence when used with sumatriptan. Cephalalgia 1999; 19:186-187.
100. Bates D, Ashford E, Dawson R, et al. Subcutaneous sumatriptan during the migraine aura. Neurology 1994; 44:1587-1592.
101. Olesen J, Diener HC, Schoenen J, Hettiarachchi J. No effect ofeletriptan administration during the aura phase of migraine. Eur J Neurol 2004; 11:671-677.
102. Diener HC. for the ASASUMAMIG Study Group. Efficacy and safety of intravenous acetylsalicylic acid lysinate compared to subcutaneous sumatriptan and parenteral placebo in the acute treatment of migraine. A double-blind, double-dummy, randomized, multicenter, parallel group study. Cephalalgia 1999; 19:581-588.
103. The Subcutaneous Sumatriptan International Study Group. Treatment of migraine attacks with sumatriptan. N Engl J Med 1991; 325:316-321.
104. Silberstein S, Douglas C, McCrory D. Ergotamine and dihydroergotamine: history, pharmacology, and efficacy. Headache 2003; 43:144-166.
105. Bigal ME, Bordini CA, Tepper SJ, Speciali JG. Intravenous dipyrone in the acute treatment of migraine without aura and migraine with aura: a randomized, double blind, placebo controlled study. Headache 2002; 42(9):862-871.
106. Leniger T, Pageler L, Stude P, Diener H, Limmroth V. Comparison of intravenous valproate with intravenous lysine-acetylsalicylic acid in acute migraine. Headache 2005; 45:42-46.
107. Diener HC, Tfelt-Hansen P. Headache associated with chronic use of substances. In: Olesen J, Tfelt-Hansen P, Welch KMA, eds. The Headaches. New York: Raven Press, 1993:721-727.
108. Kaube H, May A, Diener HC, Pfaffenrath V. Sumatriptan misuse in daily chronic headache. BMJ 1994; 308:1573.
109. Gaist D, Tsiropoulus I, Sindrup SH, Hallas J, Rasmussen BK, Kragstrup J. Inappropriate use of sumatriptan: population based register and interview study. Br J Med 1998; 316:1352-1353.
110. Gaist D. Use and overuse of sumatriptan. Pharmaco-epidemiological studies based on prescription register and interview data. Cephalalgia 1999; 19:735-761.
111. Limmroth V, Katsarava Z, Fritsche G, Przywara S, Diener H. Features of medication overuse headache following overuse of different acute headache drugs. Neurology 2002; 59:1011-1014.
112. Limmroth V, Kazarawa S, Fritsche G, Diener HC. Headache after frequent use of new 5-HT agonists zolmitriptan and naratriptan. Lancet 1999; 353:378.
113. Maassen van den Brink A, Reekers M, Bax WA, Ferrari MD, Saxena PR. Coronary side-effect potential of current and prospective antimigraine drugs. Circulation 1998; 98:25-30.
114. Maassen van den Brink A, Broek vdRWM, Vries dR, Bogers AJJC, Avezaat CJJ, Saxena PR. Craniovascular selectivity of eletriptan and sumatriptan in human isolated blood vessels. Neurology 2000; 55:1524-1530.
115. Welch KMA, Mathew NT, Stone P, Rosamond W, Saiers J, Gutterman D. Tolerability of sumatriptan: clinical trials and post-marketing experience. Cephalalgia 2000; 20:687-695.
116. Lewis PJ, Barrington SF, Marsden PK, Maisey MN, Lewis LD. A study of the effects of sumatriptan on myocardial perfusion in healthy male migraineurs using 13NH3 positron emission tomography. Cephalalgia 1997; 48:1542-1550.
117. Gnecchi-Ruscone T, Bernard X, Pierre P, et al. Effect of naratriptan on myocardial blood flow and coronary vasodilator reserve in migraineurs. Neurology 2000; 55:95-99.
118. Hall G, Brown M, Mo J, MacRae K. Triptans in migraine: the risks of stroke, cardiovascular disease, and death in practice. Neurology 2004; 62:563-568.
119. Velentgas P, Cole JA, Mo J, Sikes CR, Walker AM. Severe vascular events in migraine patients. Headache 2004; 44:642-651.
120. Shuhaiber S, Pastuszak A, Schick B, et al. Pregnancy outcome following first trimester exposure to sumatriptan. Neurology 1998; 51:581-583.
121. Kallen B, Lygner PE. Delivery outcome in women who used drugs for migraine during pregnancy with special reference to sumatriptan. Headache 2001; 41:351-356.
122. Fox AW, Chambers CD, Anderson PO, Diamond ML, Spierings ELH. Evidence-based assessment of pregnancy outcome after sumatriptan exposure. Headache 2002; 42:8-15.
123. Olesen C, Steffensen FH, Sorensen HT, Nielsen GL, Olsen J. Pregnancy outcome following prescription for sumatriptan. Headache 2000; 40:20-24.
124. O'Quinn S, Ephross SA, Williams V, Davis RL, Gutterman DL, Fox AW. Pregnancy and perinatal outcomes in migraineurs using sumatriptan: a prospective study. Arch Gynecol Obstet 1999; 263:7-12.